SCHEDULE: Highbridge Capital Reports 4.9% Stake in Karyopharm

Highbridge Capital Management, LLC has reported a 4.9% beneficial ownership stake in Karyopharm Therapeutics Inc. through warrants, subject to a 4.9% ownership blocker.

Summary

• Highbridge Capital Management, LLC, an investment adviser, reported beneficial ownership of Karyopharm Therapeutics Inc. common stock.
• The ownership is derived from warrants directly held by the Highbridge Funds.
• Highbridge Capital Management, LLC has sole voting and dispositive power over 649,984 shares.
• The reported percentage of class is 4.9%, which accounts for a 4.9% ownership blocker provision in the warrants.
• This blocker prevents Highbridge from exercising warrants if it would result in owning more than 4.9% of the outstanding common stock.
• The calculation of the percentage is based on 8,671,278 shares of Common Stock outstanding as of August 6, 2025, as reported in Karyopharm's Form 10-Q for the quarter ended June 30, 2025.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Highbridge Capital Management, LLC, a reputable investment adviser, reporting a 4.9% beneficial ownership stake in Karyopharm Therapeutics Inc. through warrants suggests a positive investment thesis. While the 4.9% blocker limits their immediate full exercise, the underlying investment in warrants indicates a belief in future value.

Positives

• An institutional investment adviser, Highbridge Capital Management, LLC, holds a significant stake (4.9%) in Karyopharm Therapeutics Inc., potentially signaling confidence in the company.
• The investment is held in the ordinary course of business, indicating a standard investment strategy rather than an activist intent.

Negatives

• The 4.9% ownership blocker limits Highbridge Capital Management's ability to fully exercise all reported warrants, potentially capping their upside from warrant exercise if the stock performs well.
• The actual number of shares beneficially owned by Highbridge Capital Management, after giving effect to the 4.9% Blocker, is less than the 649,984 shares that would be issuable upon full exercise of the reported warrants.

Risks

• The 4.9% Blocker provision in the warrants restricts Highbridge Capital Management's ability to increase its beneficial ownership beyond 4.9% of Karyopharm Therapeutics Inc.'s outstanding common stock, potentially limiting future influence or full realization of warrant value.

Future Outlook

na

Industry Context

This filing indicates an institutional investor's significant stake in a biotechnology or pharmaceutical company, Karyopharm Therapeutics Inc. Such investments are common in the industry, reflecting investor interest in specific companies or therapeutic areas, but this filing does not provide broader industry trend analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake could influence market perception and potentially share price. The 4.9% blocker might limit potential activist pressure from this specific investor.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the holding is not for control purposes.

Key Dates

Keywords

Karyopharm Therapeutics, Highbridge Capital Management, Schedule 13G, beneficial ownership, common stock, warrants, investment adviser, 4.9% blocker, institutional investor